Elecsys® β-Amyloid (1-42) CSF II

Robust and accurate biomarker tests to aid clinical decisions

Elecsys^® β-Amyloid (1-42) CSF II and Elecsys Phospho-Tau (181P) CSF are in vitro electrochemiluminescence immunoassays for the measurement of the β-Amyloid (1-42) (Abeta42) and Phospho-Tau (181P) (pTau181) protein concentrations in cerebrospinal fluid (CSF) from adult patients aged 55 years and older being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment to generate a pTau181/Abeta42 ratio value.¹

The Elecsys^® β-Amyloid (1-42) CSF II assay is not intended to be used as a stand-alone test and should only be used with the Elecsys Phospho-Tau (181P) CSF assay to calculate the ratio of phosphorylated Tau (181P) (pTau181) to β-Amyloid (1-42) (Abeta42) in CSF (pTau181/Abeta42 ratio).²

The use of the Elecsys^® assays in the pTau181/Abeta42 ratio can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.^2,3

A positive pTau181/Abeta42 ratio result in CSF does not establish a diagnosis of Alzheimer's disease (AD) and should always be interpreted in conjunction with clinical information.¹

Do You Have Any Questions?

The Power of Elecsys^® in Alzheimer’s disease

Robust, precise and accurate results to help ensure patients get the care they deserve

The importance of early diagnosis in Alzheimer's disease and mild cognitive impairment

Roche recognizes the unmet needs of patients affected by a neurological condition such as Alzheimer's Disease. Find out more about early detection csf biomarkers.

...

References

Elecsys® β‑Amyloid (1‑42) CSF II assay method sheet.
Rabinovici G.D. et al. (2019). Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 321(13), 1286-1294.
Hansson O. et al. (2018). CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14(11), 1470-1481